Biology

Noble Capital Markets and Channelchek to Host Investor Forum C-Suite Interviews During Prestigious 16th Annual World Stem Cell Summit

Friday, May 14, 2021 - 7:42pm

b'BOCA RATON, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Noble Capital Markets (\xe2\x80\x9cNoble\xe2\x80\x9d), a research-driven investment bank, today announces its platinum-level sponsorship of, and collaboration with, the 16th World Stem Cell Summit, to be held virtually June 14-18, 2021.

Key Points: 
  • b'BOCA RATON, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Noble Capital Markets (\xe2\x80\x9cNoble\xe2\x80\x9d), a research-driven investment bank, today announces its platinum-level sponsorship of, and collaboration with, the 16th World Stem Cell Summit, to be held virtually June 14-18, 2021.
  • \xc2\xa0\xe2\x80\x9cIt is our passion at Noble, and we\xe2\x80\x99re extremely excited to serve as the\xc2\xa0principal partner of the Investor Forum track at the Summit.\xe2\x80\x9d\nBernard Siegel, executive director of RMF and founder of the World Stem Cell Summit, said, \xe2\x80\x9cThere is huge investor interest in the regenerative medicine and longevity space.
  • As with all other content on Channelchek, there will be no cost to access these ChannelCasts.\nFor more information and to register for the Investor Forum and other events at the World Stem Cell Summit,\xc2\xa0please visit: https://ibn.fm/WorldStemCellSummit2021 .
  • In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade and a half.

Automated Incubators and Storage Systems Increase Throughput and Sample Protection

Friday, May 14, 2021 - 6:27pm

The systems provide speedy delivery of microtiter plates through an advanced plate shuttle system to meet the needs of high-throughput laboratories and accelerate research.

Key Points: 
  • The systems provide speedy delivery of microtiter plates through an advanced plate shuttle system to meet the needs of high-throughput laboratories and accelerate research.
  • "Through a fully automated ContraCondecontamination routine, the Cytomat 24 automated incubators and storage systemssimplify cleaning and disinfection, providing our customers with confidence in their sample integrity.
  • Customers are always looking for opportunities to increase productivity in their processes while ensuring the quality of the samples and results.
  • The Cytomat 24 automated incubators and storage systemsreduce the mean plate access time to 15 secondsallowing users to achieve their research goals in less time.

Jinfiniti and Takezo team to provide smart consumers precision health

Friday, May 14, 2021 - 6:00pm

To address this need, Augusta, Ga.-based biomarker tester Jinfiniti Precision Medicine and Portland-based supplement provider Takezo have come together to offer consumers a curated shopping experience based on their biomarker data.\nThrough this newfound partnership, consumers can take a biomarker test provided by Jinfiniti.

Key Points: 
  • To address this need, Augusta, Ga.-based biomarker tester Jinfiniti Precision Medicine and Portland-based supplement provider Takezo have come together to offer consumers a curated shopping experience based on their biomarker data.\nThrough this newfound partnership, consumers can take a biomarker test provided by Jinfiniti.
  • By assessing certain biomarkers, the test is intended to show consumers where their bodies need attention the most.
  • The results are then sent (with consumer consent) to Takezo, which will curate a bundle of products that address the consumers\' biomarker weaknesses.
  • As a result, this personalized selection of nutrition helps consumers make educated health decisions and streamlines the shopping process at the same time.

Outlook on the Medical Enzyme Technology Global Market to 2028 - Rising Production of Biopharmaceutical Products Presents Opportunities - ResearchAndMarkets.com

Friday, May 14, 2021 - 6:00pm

Abnormalities in enzyme metabolism system leads to many metabolic diseases.

Key Points: 
  • Abnormalities in enzyme metabolism system leads to many metabolic diseases.
  • Many enzymes are being widely used in the clinical examination as a specific disease marker.
  • Enzymes are the preferred markers in various disease states such as myocardial infarction, jaundice, pancreatitis, cancer, and neurodegenerative disorders.
  • However, the market for normothermic machine perfusion is estimated to grow at a higher CAGR of 4.4% during the forecast period.\nThe medical enzyme technology market, by application, is segmented into disease treatment, diagnostic tools, biomedical research, and others.

Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences

Friday, May 14, 2021 - 3:58pm

Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.

Key Points: 
  • Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.
  • Cytovia\xe2\x80\x99s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site.
  • Both platforms offer optionality to clinicians and can also be used synergistically.
  • Cytovia\xe2\x80\x99s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).\n'

Atreca to Present at Upcoming Virtual Investor Conferences

Friday, May 14, 2021 - 1:30pm

Atreca\xe2\x80\x99s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.

Key Points: 
  • Atreca\xe2\x80\x99s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.
  • These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101.
  • A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
  • These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts.

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

Friday, May 14, 2021 - 1:00pm

b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .

Key Points: 
  • b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
  • The webcast replays will be available for 90 days following each event.\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.\nMagenta is based in Cambridge, Mass.
  • For more information, please visit www.magentatx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005057/en/\n'

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

Friday, May 14, 2021 - 12:30pm

The FDA\xe2\x80\x99s Fast Track designation reinforces the urgency to address the unmet needs of patients with CAH as quickly and safely as possible.

Key Points: 
  • The FDA\xe2\x80\x99s Fast Track designation reinforces the urgency to address the unmet needs of patients with CAH as quickly and safely as possible.
  • We are grateful to have received Fast Track along with other key designations granted by the FDA and the EMA,\xe2\x80\x9d said Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy, which is focused on developing gene therapy treatment options for patients in need.
  • The disease is caused by deleterious mutations in the gene encoding an enzyme called 21-hydroxylase, leading to lack of endogenous cortisol and aldosterone production.
  • The presentation covered three key Investigational New Drug (IND)-enabling studies that informed the anticipated upcoming clinical trial for BBP-631.

Casma Therapeutics to Present at Oppenheimer Rare & Orphan Disease Summit

Friday, May 14, 2021 - 1:00pm

b'CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.\nCasma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients.

Key Points: 
  • b'CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.\nCasma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients.
  • Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases.
  • By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of several diseases such as neurodegeneration, metabolic disorders, inflammation and muscle degeneration.
  • For more information, please visit www.casmatx.com .\n'

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

Friday, May 14, 2021 - 1:00pm

\xe2\x80\x9cEnrollment in our Phase 1/2 trial of PC14586, our first in class p53 Y220C reactivator, is progressing as planned.

Key Points: 
  • \xe2\x80\x9cEnrollment in our Phase 1/2 trial of PC14586, our first in class p53 Y220C reactivator, is progressing as planned.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
  • Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.